Hoensch H P, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus E E
Eur J Clin Pharmacol. 1985;28(4):475-7. doi: 10.1007/BF00544371.
Six patients with primary biliary cirrhosis (PBC) were treated with a daily oral dose of 600 mg rifampicin for 2 weeks to induce the hepatic metabolism of drugs and bile acids. On rifampicin 5 of 6 patients experienced a pronounced decrease of their pruritus. In all patients the oxidative cytochrome P-450 dependent drug metabolism was induced as shown by an increase of antipyrine-clearance from 36.3 +/- 8.8 to 80.6 +/- 20.1 ml/min and an enhanced urinary excretion of 6-beta-hydroxycortisol from 454 +/- 1.99 to 1607 +/- 362 micrograms/24 h. Furthermore, in all 6 patients the serum alkaline phosphatase declined. In the 3 cholestatic patients (bilirubin greater than 1.0 mg/dl) the serum concentration of total and conjugated bile acids was strikingly reduced. Thus, rifampicin is an inducer of hepatic metabolism in PBC-patients, ameliorates the pruritus and can lower serum concentrations of alkaline phosphatase and bile acids.
6例原发性胆汁性肝硬化（PBC）患者接受每日口服600mg利福平治疗2周，以诱导药物和胆汁酸的肝脏代谢。服用利福平后，6例患者中有5例瘙痒明显减轻。所有患者的氧化细胞色素P-450依赖性药物代谢均被诱导，表现为安替比林清除率从36.3±8.8ml/min增加到80.6±20.1ml/min，6-β-羟基皮质醇的尿排泄量从454±1.99μg/24h增加到1607±362μg/24h。此外，所有6例患者的血清碱性磷酸酶均下降。在3例胆汁淤积患者（胆红素大于1.0mg/dl）中，总胆汁酸和结合胆汁酸的血清浓度显著降低。因此，利福平是PBC患者肝脏代谢的诱导剂，可改善瘙痒，并可降低血清碱性磷酸酶和胆汁酸浓度。
